Sofosbuvir

• UNSPSC Description:

  Sofosbuvir (GS-7977) is an HCV RNA replication inhibitor with an EC50 of 92 nM[1].

• Target Antigen:

  HCV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/PSI-7977.html

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)|H2O : 25 mg/mL (ultrasonic;warming;heat to 50°C)

• Smiles:

  C[C@@]1(F)[C@H](O)[C@@H](CO[P@](OC2=CC=CC=C2)(N[C@@H](C)C(OC(C)C)=O)=O)O[C@H]1N(C=CC(N3)=O)C3=O

• Molecular Weight:

  529.45

• References & Citations:

  [1]Murakami E, et al. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977.J Biol Chem. 2010 Nov 5;285(45):34337-47.|[2]Lam AM, et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother. 2012 Jun;56(6):3359-68.|[3]Sofia MJ, et al. Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem. 2010 Oct 14;53(19):7202-18.|[4]Zhang X, et al. Discovery and evolution of aloperine derivatives as a new family of HCV inhibitors with novel mechanism. Eur J Med Chem. 2018 Jan 1;143:1053-1065.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Launched

• CAS Number:

  1190307-88-0